1Assistant Professor, Department of Genetics, M.D. University, Rohtak-124001
2Senior Professor, Department of Pathology, Pt. B.D. Sharma University of Health Science, Rohtak
3Research Scholar, Department of Genetics, M.D. University, Rohtak-124001
*Correspondance: Dr. Ritu Yadav, Assistant Professor, Dept. of Genetics, M.D. University Rohtak, Haryana. E mail: ritugenetics@gmail.com, Ph. No.: 07404240801
Online published on 13 January, 2015.
Role of hormone receptors as a prognostic and therapeutic tool in breast cancer is widely accepted. The aim of this study was to analyze the role of steroid receptor in breast cancer subtyping with clinicopathological factors. In the present study, immunohistochemical assay of two hundred patients of breast carcinoma was performed to know the hormone receptor status as well as pathological examination. Breast cancer patients were classified into different groups based on IHC profile (ER/PR and Her2/neu expression) and their relation with traditional prognostic parameters. Frequency of ER-PR- Her- subtype found to be maximum in all subtypes. The frequency of patients with ER-PR-Her+ were observed second in sub typing, only a few patients were observed with subtype ER+PR-Her-, ER-PR+ Her+, ER-PR+ Her-. Maximum patients were observed with the grade I (59%) and infiltrate ductal carcinoma type (59.7%) whereas a few were lobular carcinoma type (40.3%). Majority of the breast cancer patients (43%) had tumor size 2–4.9cm. A large proportion of patients (58.5%) had <4 positive lymph nodes status. In conclusion further efforts are needed to be focused the standardization of different therapies responses on biological subtypes and development of further reproducible testing.
Breast cancer subtypes, IHC, Hormonal receptor expression, Estrogen, Progesterone, Her-2/neu receptor
